Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor

neutrophil count
btk inhibitor
flow cytometry
bendamustine
gilbert's syndrome
  • 23 views
  • 26 Feb, 2022
  • 1 location
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK

neutrophil count
btk inhibitor
monoclonal antibodies
platelet count
gilbert's syndrome
  • 0 views
  • 26 Apr, 2022
  • 1 location
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) with indoximod (IDO-inhibitor) during chemotherapy will synergistically enhance anti-tumor immune

neutrophil count
tyrosine
cytotoxic chemotherapy
medulloblastoma
antiepileptic
  • 0 views
  • 23 Apr, 2022
  • 1 location
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

is considered experimental. Experimental means that it is still being tested to see if it is safe and effective. Ibrutinib is a new drug known as a 'Bruton's Tyrosine Kinase (BTK) inhibitor

tyrosine
mantle cell lymphoma
lymphoma
hematologic malignancy
ibrutinib
  • 88 views
  • 29 Jan, 2022
  • 1 location
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma (ALTAMIRA)

bruton tyrosine kinase (BTK) inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more

neutrophil count
tyrosine
btk inhibitor
bendamustine
mantle cell lymphoma
  • 0 views
  • 21 Mar, 2022
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

measurable disease
bone marrow procedure
cancer
  • 0 views
  • 09 Jul, 2022
  • 17 locations
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid malignancies. Cirmtuzumab is a monoclonal antibody that attaches to a protein (called ROR 1) that is found on hematologic tumor cells. ROR1 has …

neutrophil count
btk inhibitor
monoclonal antibodies
hepatitis b surface antigen
ibrutinib
  • 40 views
  • 07 Jul, 2022
  • 8 locations
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.

  • 0 views
  • 11 Jul, 2022
  • 1 location
Study of Acalabrutinib and Tafasitamab in MZL Patients

This is a multicenter open label phase II trial in patients with previously treated Marginal Zone Lymphomas. The aim of the study is to evaluate the efficacy and the safety of tafasitamab in combination with acalabrutinib. Twenty-four patients are expected to be enrolled and treated every 28 days with acalabrutinib …

  • 0 views
  • 22 Jul, 2022
  • 10 locations
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101) Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

CLL2-BZAG is a prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL.

neutrophil count
btk inhibitor
ibrutinib
hepatitis b core antibody
chronic lymphocytic leukemia
  • 0 views
  • 13 Oct, 2021
  • 15 locations